Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for September 5, 2024, at 4:05 p.m. ET in New York.
Management will engage in a fireside chat during the conference. Investors and interested parties can access a live webcast of the presentation through Dyne's website in the Investors & Media section. The replay will remain available for 90 days after the event.
This participation highlights Dyne's commitment to advancing innovative therapeutics for individuals with genetically driven muscle diseases and provides an opportunity for the company to share insights with the healthcare investment community.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, DYN gained 0.56%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on Thursday, September 5, 2024 at 4:05 p.m. ET.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contact:
Amy Reilly
areilly@dyne-tx.com
857-341-1203
FAQ
When is Dyne Therapeutics (DYN) presenting at the Morgan Stanley Healthcare Conference?
How can I watch Dyne Therapeutics' (DYN) presentation at the Morgan Stanley conference?
How long will the replay of Dyne Therapeutics' (DYN) Morgan Stanley conference presentation be available?
What is the focus of Dyne Therapeutics (DYN) as a company?
